USP6 and Ewing sarcoma: On a final note, we posit that due to USP6’s ability to promote a hot TME and broad innate immune activation (20), it holds promise not only as a monotherapy for Ewing sarcoma (44, 45), but also for other malignancies and in combination therapy.